Regenerative medicines have the attention of investors, industry players, and regulatory authorities. Prompted by an influx of funding in the regenerative medicines sector, drug developers have jumped forward with clinical development of product candidates. Factors that remain critical to the successful development of regenerative medicines include raw material sourcing and overcoming manufacturing bottlenecks.
